Teva Pharmaceutical Industries Ltd. (TEVA)

11.57
0.19 1.62
NYSE : Health Technology
Prev Close 11.76
Open 11.80
Day Low/High 11.20 / 11.94
52 Wk Low/High 6.07 / 13.76
Volume 11.69M
Avg Volume 10.87M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 12.57B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

Here Are 3 Stocks With Huge Potential

Two are biotechs and one is in cyber security.

Strong Economy Will Push Israeli Stocks Higher Says Aberdeen Fund Manager

Strong Economy Will Push Israeli Stocks Higher Says Aberdeen Fund Manager

The Israeli economy is strong, growing fast and offers good value, according to William Scholes, investment manager for Aberdeen Asset management.

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Jim Cramer answers your Twitter questions about FireEye (FEYE) and other stocks from the floor of the New York Stock Exchange.

Health Care Mergers Are Just Getting Started

Deals coming fast and furious in the best group in town.

Deluge of Deals Isn't About to Dry Up

Acquisitions cut into overabundance of companies.

Day Ahead: M&A Rumor Mill

Merger rumors abound around salesforce.com.

Market Wrap: GDP, Fed Are Flops

Market Wrap: GDP, Fed Are Flops

Consumer, health care names lead market lower.

Rising Interest Rate Environment Won't Derail Merger Fund

Rising Interest Rate Environment Won't Derail Merger Fund

The Merger Fund seeks absolute returns and is not correlated to the stock market so it will fare well in a rising rate environment.

Dealmaking Frenzy Leads to Heady Days for Event-Driven Funds

Dealmaking Frenzy Leads to Heady Days for Event-Driven Funds

The surge in deal-making has created the ideal environment for merger arbitrage or event-driven funds, said K.C. Nelson, portfolio manager for the Driehaus Event Driven Fund.

Stocks Slump as Biotech Sector Drags Nasdaq From Records

Stocks Slump as Biotech Sector Drags Nasdaq From Records

Stock losses escalated in the closing minutes of Monday's session.

Partnerships Lift Small Caps

Partnerships Lift Small Caps

Watch for small biotechs partnering with bigger firms.

Japanese Stocks Hit 15-Year High

And four other things you need to know now.

Market Wrap: Major Indexes End Mixed

Market Wrap: Major Indexes End Mixed

U.S. stocks were mixed on Tuesday.

Earnings and Marriage Season

Earnings and Marriage Season

Biotech companies are saying, "I do."

Deal or No Deal, Stick With Mylan

Deal or No Deal, Stick With Mylan

Teva bid highlights M&A action in health care sector.

Deal or No Deal, Stick With Mylan

Deal or No Deal, Stick With Mylan

Teva bid highlights M&A action in health care sector.

Say It With Me: Specialty Pharma

These companies are the hottest thing going.

Small-Cap M&A Flies Under the Radar

Small-Cap M&A Flies Under the Radar

Recent activity has heated up and is creating shareholder value.

Teva Shares Go for the Pennant

Teva Shares Go for the Pennant

In breakout mode, the stock is looking to continue its upward path.

Feeling Good About Pharmaceuticals

With so much M&A action, now's the time to invest in the sector.

Teva upgraded at Oppenheimer

Market Wrap: Out Like a Lion

Stocks post solid gains with the S&P breaking a losing streak.

The 7 Pillars of Healthcare Strength

The 7 Pillars of Healthcare Strength

Here are healthcare stocks of all shares and sizes with strong charts.

Dynavax Technologies: A New 'Best Idea'

Dynavax Technologies: A New 'Best Idea'

This vaccine maker is now closer to several important milestones.

Eagle Pharmaceuticals: Still a 'Best Idea'

Eagle Pharmaceuticals: Still a 'Best Idea'

A transformational deal with Teva makes it an even better play.

Eagle Pharmaceuticals: Still a 'Best Idea'

Eagle Pharmaceuticals: Still a 'Best Idea'

A transformational deal with Teva makes it an even better play.

Small-Cap Friday's Little Gem

Small-Cap Friday's Little Gem

One small pharmaceutical company has big potential.

Take a Look at Teva

Take a Look at Teva

We like new initiatives and see solid upside potential.

Teva upgraded at Sterne Agee